Experts of the Pharmacoeconomics Department are leading a three-year EU4Health project “Capacity building to support the uptake of biosimilars in a multistakeholder approach” (AUGMENT Biosimilars).
The first year of the AUGMENT Biosimilars project focused on a comprehensive study on policies to improve the uptake of biosimilar medicines. The study has just been published and is available for download.
- Link to the study report: https://data.europa.eu/doi/10.2925/2261232
- Annex 7 (country fiches): https://data.europa.eu/doi/10.2925/9409811
- Annexes 1-6, 8-11 : https://data.europa.eu/doi/10.2925/0897789
The study maps biosimilar policies and practices across 32 European countries. It offers an analysis of the impact of biosimilar policies on the availability, affordability and accessibility of biosimilars across Europe. The study report is accompanied by country fiches on biosimilar policies and practices for each of the 32 study countries.
Key findings include:
- Biosimilars contribute to improved accessibility to biological therapies.
- An increasing number of European countries are implementing biosimilar policies.
- Availability and uptake of biosimilars still varies substantially between countries.
- A well-designed mix of policy measures can contribute to improved biosimilar update.
- Public authorities need to be prepared to harness the benefits of biosimilars.
In Year 2 and 3 of the AUGMENT project, the study findings will inform the design of the capacity-building activities with different stakeholders.
Last update: 3 December 2025